Abstract: OBJECTIVE: To assess the clinical importance of on-treatment function testing of platelets in patients on aspirin after catheter-based vascular interventions. MATERIALS AND METHODS: In 109 patients with symptomatic peripheral arterial disease (PAD) of the lower limbs, platelet function testing (adenosine diphosphate-, collagen-and epinephrine-induced aggregation using light transmission aggregometry) was performed before and at multiple time points up to 1 year after a percutaneous angioplasty. Using univariate mixture models and Box-Cox transformation to ensure normally distributed individual variances, we investigated if an intraindividual variability exists and if it has a consequence for clinical outcome. RESULTS: Response to aspirin as measured by platelet aggregometry varies considerably over time in most patients. However, the intraindividual variance over time was not significantly correlated either with restenosis/reocclusion after 1 year or with adverse long-term outcome (occurrence of death for cardiovascular cause, stroke or myocardial infarction in up to 8 years follow-up). CONCLU-SIONS: Response to aspirin does not seem to have a role in determining long-term outcome in patients with symptomatic PAD. The fact that testing of platelet function at only one time point has reduced significance may have implications for all clinical settings in which aspirin is used for the prevention of thrombo-embolic events. 
Introduction
Aspirin (acetylsalicylic acid; ASA) is one of the most important drugs used for the prevention of thromboembolic vascular events. A highly variable interindividual platelet response to the treatment with aspirin has been reported. 1 "Aspirin resistance" is defined differently by different groups. Clinically, "aspirin resistance" or hyporesponsiveness occurs in patients who, although being on therapeutic doses of aspirin, develop thromboembolic cardiovascular events. 2 Others, however, have supported not including "thromboembolic events while on aspirin" as a clinical definition for aspirin resistance as only about one fourth of all vascular complications can be prevented by any one pharmacological therapy alone. 3 Biochemical assessment of platelet function may detect hypo-or non-response of platelets to aspirin therapy. However, to date, it is not clear which of several available laboratory methods has the best reliability and, in particular, the highest predictability for clinical events. 4 A recent meta-analysis of 20 studies using different aggregation tests to assess individual platelet response to aspirin demonstrated an elevated cardiovascular risk associated with aspirin resistance. 5 Therefore, although the clinical importance of non-responsiveness is not yet fully understood, there is evidence for its clinical relevance. Furthermore, in patients with cerebrovascular ischemic events being on aspirin for secondary stroke prophylaxis, nonresponsiveness was significantly associated with recurrent ischemia. 6 Peripheral arterial disease (PAD), in particular of the lower limbs, is highly prevalent especially in the elderly population. 7 Its utmost importance as a marker of atherosclerotic vascular disease in general has been confirmed. 8 Percutaneous transluminal angioplasty (PTA) to revascularize peripheral arteries is an established treatment in symptomatic patients. Aspirin is given routinely to patients being treated for peripheral arterial disease and has been shown to reduce the risk of reocclusion after vascular procedures. 9 Therefore, response to aspirin in this setting is of great importance.
A previous study analyzing the time course of agonist-induced platelet aggregation in patients who underwent PTA of the lower limbs provided inconclusive results and was only limited to a 12 months' follow-up. 10 Here, we wanted to investigate if, apart from the known variable interindividual platelet response to aspirin, an intraindividual variability also exists, and, if so, whether such an intraindividual variance has a consequence for clinical outcome. To this end, individual variances were correlated first with the occurrence of restenosis/reocclusion in patients after PTA of the lower limbs within one year. Secondly, we tested the hypothesis that defined clinical endpoints (e.g. cardiovascular events such as myocardial infarction, stroke, peripheral re-intervention) during long-term follow up of up to almost eight years are more often reached in patients with a high variance.
Materials and methods

Patients
The current study was done as a substudy of a previously published trial. 11 Over a three-year- Mean follow-up was 80 months (range 52-94 months). Owing to the parallel group design of the original trial, 11 patients had initially been randomized to one of two treatment arms (no additional treatment versus dalteparin, 5000 IU subcutaneously once daily on day 1 and 2 after the intervention followed by 2500 IU once daily for 90 days in addition to aspirin 100 mg daily). Unpaired t-test revealed that, after three months, neither for ADP (p = 0.4942, ns), nor for epinephrine (p = 0.9594, ns) or collagen (p = 0.5541, ns) any significance of an influence of dalteparin on parameters of platelet aggregation could be observed. Therefore, patients that had received dalteparin within the first three months after angioplasty were also included into the current study.
Follow-up and end points
ADP-, collagen-, and epinephrin-induced platelet aggregation was assessed before, and at 1, 
Testing of platelet function
ADP-, collagen-, and epinephrin-induced platelet aggregation were assessed by light transmittance aggregometry (LTA). In the fasting and resting patient, blood was taken from an antecubital vein via i. v. cannula (1.2 mm) directly into silicon-coated vacutainer tubes containing 0.5 ml buffered sodium citrate (3.8 %). Samples were processed immediately, and platelet aggregation was measured after centrifugation (100 G, 10 min, room temperature) of citrated blood (3.8%; 1:10) to get platelet-rich plasma (PRP). In addition, the remaining sample was further centrifuged at a higher rate (3000 G, 15 min, RT) to obtain platelet pure plasma (PPP). To determine platelet aggregation to the different agonists, a standardized plasma sample with a total platelet count of 250 G/ l was used by adjusting PRP with PPP.
Platelets were stimulated with epinephrine (final concentration 0.1 mmol/l), collagen (final concentration 5 mg/l) and ADP (final concentration 0.002 mol/l), and aggregation was measured using an APACT 4 aggregometer (Ahrensburg, Germany). Aggregation was expressed as the maximum percentage change in light transmittance from baseline.
The coefficient of variation (CV) for LTA in our laboratory was 8.9% (n=20).
Statistical analysis
For data management and analysis the statistical software package R, version 2.6.1 (R Development Core Team, Vienna, Austria) was used. Continuous variables are reported as means ± SD, categoric variables as counts and percentages. Pearson's correlation was used to check if two continuous variables were strongly correlated, so that they could be treated as exchangeable. The Mann Whitney U test was used for comparisons of continuous variables, the chi-squared test for comparisons of categorical variables. A p value < 0.05 was considered to be statistically significant.
Univariate mixture models:
For each timepoint and each of the three measures (ADP, collagen, epinephrine) we first fit three different univariate models: one using the ordinary normal distribution, one using a mixture of two normal distributions with equal variances and one using a mixture of two completely distinct normal distributions. The different models were calculated using an expectation-maximization (EM) algorithm. They were compared graphically and via the Akaike's information criterion (AIC). The model with the smallest AIC for each timepoint has been selected.
Box-Cox-transformation:
To compare variances of ADP-, collagen-, or epinephrine-induced platelet aggregation over time between patients with and without restenosis and between patients reaching one of the endpoints and those who did not, a t-test can only be performed if these variances are approximately normally distributed in both groups. As this was not the case, we used the Box-Cox transformation to achieve normality. We decided to use the quartic root (i.e. the squareroot of the standard deviation) of the variances of ADP, collagen, and epinephrine. Furthermore, in order to appropriately incorporate the fact of variable numbers of measurements in different individuals into the analyses, a weighted t-test was used. To avoid the problem of multiple testing, Bonferroni correction was used.
Results
Baseline demographic and clinical characteristics as well as laboratory variables are shown in 1B) . Apart from these differences, the groups were similar with respect to their baseline parameters.
Mean values of ADP-, epinephrine-and collagen-induced platelet aggregation, as assessed by LTA, for all patients up to one year after the initial percutaneous procedure are shown in Table 2 .
When comparing these values between patients with any event and those without during longterm follow-up, no significant differences could be detected.
Only 25.6% of the patients were sampled at 12 months, and 52 % of all patients had their agonist-induced platelet aggregation measured at ≥ three timepoints (table 2) . However, in order to circumvene this problem, and to analyze individual variances in the best possible way under these circumstances, a weighted t-test was performed.
We then wanted to investigate if subgroups exist, i.e. patients whose values for platelet aggregation upon stimulation are at all timepoints higher or lower than the average. To this end, we first plotted all data separately for each individual. There was a considerable amount of variation in most of the individuals. As outlined above, we therefore tried to fit mixture distributions in the univariate (i. e. for all timepoints separately) case. For each timepoint we chose for ADP (epinephrine and collagen not shown) the best out of three possible univariate models (normal distribution; mixture of two normal distributions with equal variances; mixture of two distinct normal distributions). A mixture of two normal distributions with distinct variances was chosen for time points 0 and 12. A mixture of two normal distributions with equal variance was chosen for timepoints 3 and 6.
One normal distribution was chosen for timepoint 1.
Figure 2.
We found there was no distinct subgroup detectable which would remain the same over the observed time period.
We also calculated correlations of the agonists ADP, epinephrine and collagen for all five timepoints. Although there was a positive correlation remaining relatively constant over time, this correlation is not strong (between r=0.25 and r=0.64). Therefore, we did not treat the agonists as exchangeable.
We then wanted to analyze whether the initially observed high variance of ADP-, epinephrine-, and collagen-induced platelet aggregation within any individual patient might have a significant influence on the occurrence of restenosis/reocclusion (within one year after PTA) and/ or the combined endpoint (during complete long-term follow-up). Results of a weighted t-test are shown in Table 3 .
In all but one constellation there was no evidence for a difference between the groups. Only for the time course of collagen, a p-value below 0.05 indicated a significant difference with respect to the occurrence of restenosis/reocclusion. However, in this context, the multiple testing problem has to be borne in mind, so that the probability of a wrong significant result cannot be controlled via α = 0.05 any more. The appropriate level of significance resulting from the Bonferroni correction is 0.008. Therefore, no evidence for a difference between the groups could be found.
Discussion
In our study with its unique aspects of multiple time points of platelet function testing and a very long clinical follow-up we found that platelet aggregation results using light transmission aggregometry in symptomatic patients with PAD intraindividually vary considerably over time and do not correlate with long-term outcome. To the best of our knowledge, this is the first study to describe this. Others have recently reported a high intra-individual variability of ADP-and collagen-induced platelet aggregation. 13 However, these findings were observed in healthy individuals receiving aspirin for up to eight weeks only whereas we describe this for the first time in a pathophysiologic context. Furthermore, we had multiple time points for platelet function testing during a long period of twelve months and correlated our findings with clinical endpoints during a follow-up of up to eight years.
Because of the missing values especially for the later timepoints, it was difficult to fit complex mixture distributions. However, we could circumvene this problem by using a weighted t-test. We cannot rule out that variable numbers of measurements in different individuals might possibly have affected our data on the correlation between intraindividual variance and long term cardiovascular outcome. However, our main conclusion (i.e. that testing of platelet function at one timepoint only has reduced significance) remains unaffected.
This finding may potentially entail serious implications, as it means that on-treatment function testing of aspirin, done at one timepoint, usually before a peripheral or coronary intervention in certain patients at individually high risk for thrombosis, has a reduced significance, at least when LTA is used. This could also mean that a correlation between response to aspirin and clinical events (as shown in several studies in the past) has to be interpreted with caution.
Low-dose daily aspirin is a widely accepted strategy for secondary prevention in patients with vascular disease. It is still a matter of controversy if the biochemical detection of hypo-or non-responsiveness to aspirin has a clinical meaning, i. e. an association with thrombotic events. However, in our study we could not show that the individually high variance translates into a higher risk for restenosis/reocclusion after PTA or for the occurrence of a major cardiovascular event.
We further found no obvious hint for the existence of subgroups of patients in which platelet aggregation testing revealed a lack of response to aspirin at all time points. With univariate mixture models fit to find the correct location for each individual within the mixture clearly separated patients could not be identified.
An interesting hypothesis which arises from our work is that a single patient being a responder to aspirin once will not always be a responder.
In this context, the different etiologies for "aspirin resistance" have to be borne in mind.
One of the most important reasons for "aspirin resistance" is a lack of compliance. 14, 15 However, virtually all our patients had been on aspirin at the beginning of the study. The variation in platelet response to agonists as depicted in figure 1 would imply a high degree of irregularity in taking aspirin which makes this explanation completely speculative. In a previous study platelet hyporesponsiveness to aspirin was evaluated in 24 patients at day ten and one month after coronary artery bypass graft surgery. 16 The authors found that although most patients could be classified as "aspirin-resistant" shortly after their operation, responsiveness to aspirin was restored in a majority of the patients at one month' follow-up . 16 We used in the present work a completely different study design in a different group of patients. Furthermore, we here describe a high degree of individual variance in the platelet responsiveness to aspirin rather than a restoration of platelet function. However, our data also point to a transient nature of response to aspirin, implying its modifiability.
In this study, we did not aim to identify possible modulating factors nor to tackle the question whether a defective action of aspirin on the arachidonic acid pathway, insufficient bioavailability, inadequate, i. e. too low dosage or a progression of peripheral artery disease are causally involved. 17, 18 However, none of the afore mentioned causes could really explain the phenomenon described here.
Platelet alterations have previously been described in patients with peripheral arterial disease. 19 Thus, it is conceivable that platelet-plaque interaction and/or platelet-injured endothelial cell interaction may modulate platelet function to a variable degree, depending on the actual state of disease, influenced by inflammatory processes.
Strong evidence linking "aspirin resistance" assayed ex vivo and the future risk of myocardial infarction, stroke or cardiovascular death came from a nested case-control study on a subgroup of patients enrolled in the HOPE study. 20 In the current study, it was not our principal aim to merely correlate response to aspirin with clinical long-term outcome.
Interestingly, in a previous reproducibility study specifically designed to measure platelet aggregation over time, very consistent results were found in a small proportion of individuals exhibiting an unusual hyperreactivity to agonists. 21 However, this study had been performed in healthy volunteers not being on aspirin.
Our results cast doubt on the significance of platelet function testing using LTA in patients while being on aspirin when assessed at one timepoint only. Our data may imply that the modalities of such tests will have to be refined in the future. 
